Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is a healthcare technology company with a positive outlook, as they have a successful SaaS platform and are seeing positive momentum in their backlog, biopharma sector, and US market. With their recent deals with US health systems and plans to become profitable in the second half of 2027, they aim to achieve profitability in the medium term and have a target price of $8. The company is also expanding their partnership with the Mayo Clinic and targeting large deals, which indicates potential for further growth and success in the future.

Bears say

Sophia Genetics is facing challenges with its declining revenue per analysis, which can partially be attributed to headwinds with biopharma customers in different regions. Additionally, its main focus on capturing longitudinal patient data and building a global sales presence has not been fully valued by investors, resulting in a negative view. While the company has had some recent success in the pharmaceutical industry, it is still facing challenges in certain regions and has yet to fully capitalize on its data-driven medicine platform.

SOPH has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 2 analysts, SOPH has a Strong Buy consensus rating as of May 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.